Published in New England Journal of Medicine · View the paper (DOI)
A new leishmaniasis vaccine, developed using CRISPR gene-editing technology, is set to begin testing in healthy people for its safety and immune response. The vaccine has shown strong results in mice and has cleared a key FDA hurdle, paving the way for Phase 2 trials aiming to understand its effectiveness.
Coverage from 2 institutions
- Phase 1 clinical trial set to begin on first leishmaniasis vaccine Ohio State University · Jun 2, 2026 · first to report
- New vaccine offers hope against growing tropical disease in U.S. Ohio State University Wexner Medical Center · Jun 24, 2026